Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Keywords immunotherapy immune checkpoint inhibitor dual ICB durvalumab tremelimumab head and neck squamous cell carcinoma progenitor exhausted T single-cell RNA single-cell TCR Introduction Head and neck cancer is a type of malignancy, with squamous cell carcinoma accounting for over 90% of cases.1 Recently approved immune checkpoint inhibitors (ICIs) such as nivolumab and pembrolizumab have changed treatment plan for recurrent and metastatic head and neck squamous carcinoma (R/M HNSCC).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.